inclusion criteria: - from 18 to 50 years old in phase 1, from 12 to 75 years old in phase 2 - body mass index (bmi) between 18 and 28 kg/m2 - the subject has good health, is assessed through medical history, clinical examination, and laboratory tests (such as hematology, biochemistry, urine ...) within the normal range evaluated by the clinician. - subjects aged potentially pregnant should use effective contraceptive methods 4 weeks prior to screening and during the study and last until 6 months after the last injection. - able and willing to participate in all activities in the clinical trial, including 6-month follow-up after vaccination. - sign the consent form. for a subject from 12 to 17 years old, it is necessary to have a legal guardian sign the consent form to participate in the study

inclusion criteria: - from 18 to 50 years old in phase 1, from 12 to 75 years old in phase 2 - body mass index (bmi) between 18 and 28 kg/m2 - the subject has good health, is assessed through medical history, clinical examination, and laboratory tests (such as hematology, biochemistry, urine ...) within the normal range evaluated by the clinician. - subjects aged potentially pregnant should use effective contraceptive methods 4 weeks prior to screening and during the study and last until 6 months after the last injection. - able and willing to participate in all activities in the clinical trial, including 6-month follow-up after vaccination. - sign the consent form. for a subject from 12 to 17 years old, it is necessary to have a legal guardian sign the consent form to participate in the study